drugset / Trial / NCT06337162
Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)
NaSingle-groupOpen-labelTreatment
Summary
This is a pilot safety study of the oral PD-L1 inhibitor INCB099280 in patients with HCC awaiting liver transplant.
Timeline
- Start
- 2024-05-01
- Primary completion
- 2027-05-01
- Completion
- 2028-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INCB099280 | Unknown | 400 mg | Oral |